Characterization of the specificity of peptide binding to four DR haplotypes.
This study describes the establishment of a peptide-binding assay for purified, detergent-solubilized DR molecules. For each of the DR specificities and peptides studied, a unique pattern of interaction was observed. Excellent correlation was detected between the DR1-, 2-, 5-, and 52a-binding capacities and the known DR restrictions of a panel of synthetic peptides. This supports the immunologic relevance of the binding assay, and emphasizes the importance of determinant selection in defining the immune response of individuals. We have also examined the capacity of a panel of DR-restricted peptides to compete with one another for binding to DR1. The results obtained are compatible with a single peptide-binding site on DR molecules. The peptide-binding capacity of the four different DR types (DR1, DR2, DR5, and DR52a) has been further examined by testing a collection of 133 different peptides. This collection is unbiased with respect to previously known DR binding and restrictions, and includes peptides of eukaryotic, bacterial, and viral origins. It was found that: 1) approximately 15 to 35% of the peptides tested bound any given DR type; 2) DR-binding capacities appeared to correlate with each other, suggesting that different alleles of the DR isotype may recognize related structures on an Ag molecule; and 3) despite the statistical correlation between binding capacity of different DR types, approximately 50% of the peptides that were positive binders still were specific in that they could bind only one of the four DR molecules tested. Degenerate binding (i.e., binding to most or all the DR molecules tested) was detected in only a minority of the cases analyzed (approximately 25%).
O'Sullivan
D
D
Cytel, La Jolla, CA 92037.
Sidney
J
J
Appella
E
E
Walker
L
L
Phillips
L
L
Colón
S M
SM
Miles
C
C
Chesnut
R W
RW
Sette
A
A
D000595:Amino Acid Sequence; D002460:Cell Line; D006678:HIV / Q000235:genetics / Q000276:immunology; D006684:HLA-DR Antigens / Q000378:metabolism*; D006239:Haplotypes; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000378:metabolism; D008285:Major Histocompatibility Complex; D008836:Micrococcal Nuclease / Q000235:genetics / Q000276:immunology; D008969:Molecular Sequence Data; D009113:Muramidase / Q000235:genetics / Q000276:immunology; D010455:Peptides / Q000138:chemical synthesis / Q000378:metabolism*; D010741:Phospholipases A / Q000235:genetics / Q000276:immunology; D011485:Protein Binding; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D001613:beta 2-Microglobulin / Q000235:genetics / Q000276:immunology
D006684:HLA-DR Antigens; D010455:Peptides; D014764:Viral Proteins; D001613:beta 2-Microglobulin; D010741:Phospholipases A; D008836:Micrococcal Nuclease; D009113:Muramidase